Perinatal asphyxia

Orphan designation: melatonin Treatment of perinatal asphyxia, 02/04/2012 Positive

Retrieved on: 
Mardi, avril 9, 2024
Eurostat, Diagnosis, Civil service commission, Research, Brain, Disability studies, Survival, Asphyxia, Patient, Committee, Knowledge, Regulation, Child, Melatonin, EMA, IRIS, Thermoregulation, Intellectual, European, COMP, Oxygen, Safety, European Commission, Placenta, Hypothermia, Blood, Umbilical cord, Marketing, Perinatal asphyxia, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    On 2 April 2012, orphan designation (EU/3/12/978) was granted by the European Commission to Dr Nicola J Robertson, United Kingdom, for melatonin for the treatment of perinatal asphyxia.
  • At the time of orphan designation, there was no treatment for perinatal asphyxia authorised in the EU.
  • Key facts
    - Active substance
    - melatonin
    - Intended use
    - Treatment of perinatal asphyxia
    - Orphan designation status
    - Positive
    - EU designation number
    - EU/3/12/978
    - Date of designation
    - Sponsor
    UCL Research Limited
    Review of designation
    The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

DGAP-News: InfanDx completes two-year follow-up study AAMBI2 of newborns with suspected perinatal asphyxia

Retrieved on: 
Jeudi, novembre 5, 2020
Biomarkers, Biology, Clinical medicine, Medicine, Respiratory diseases, Neonatology, Perinatal asphyxia, Asphyxia

InfanDx AG, a diagnostics company specialized in the development of biomarker-based tests, today announced the completion of recruitment for its two-year follow-up study AAMBI2 (Asphyxia Associated Metabolite Biomarker Investigation 2).

Key Points: 
  • InfanDx AG, a diagnostics company specialized in the development of biomarker-based tests, today announced the completion of recruitment for its two-year follow-up study AAMBI2 (Asphyxia Associated Metabolite Biomarker Investigation 2).
  • The study examined the health outcomes of children who might have suffered an oxygen deficit during birth (perinatal asphyxia).
  • InfanDx is developing the InfanDx HypoxE-test(R) for the rapid and reliable diagnosis of perinatal asphyxia.
  • For the AAMBI2 study, participants of the original study were evaluated after two years to obtain detailed information on their health outcomes.

Surging Infant COPD Cases to Catapult Manual Resuscitator Market to Greater Heights, Future Market Insights

Retrieved on: 
Lundi, août 17, 2020
Medical specialties, Medicine, Health care, Medical equipment, Resuscitator, Intensive care medicine, Bag valve mask, Neonatology, Perinatal asphyxia

DUBAI, U.A.E, Aug. 17, 2020 /PRNewswire/ -- Future Market Insights' recently published report concludes that the global manual resuscitator market will expand moderately from 2020-2030.

Key Points: 
  • DUBAI, U.A.E, Aug. 17, 2020 /PRNewswire/ -- Future Market Insights' recently published report concludes that the global manual resuscitator market will expand moderately from 2020-2030.
  • This is providing a fertile ground for manual resuscitator manufacturers to enhance their revenue pools.
  • Such rising cases of lung disorders is prompting healthcare providers to augment their spending on manual resuscitators, providing massive traction to its growth prospects in the future.
  • Koninklijke Philips launched the Augmented Infant Resuscitator in April 2018 to cater to birth asphyxia patients, an add-on device for conventional neonatal bag value mask resuscitators.

Surging Infant COPD Cases to Catapult Manual Resuscitator Market to Greater Heights, Future Market Insights

Retrieved on: 
Lundi, août 17, 2020
Medical specialties, Medicine, Health care, Medical equipment, Resuscitator, Intensive care medicine, Bag valve mask, Neonatology, Perinatal asphyxia

DUBAI, U.A.E, Aug. 17, 2020 /PRNewswire/ -- Future Market Insights' recently published report concludes that the global manual resuscitator market will expand moderately from 2020-2030.

Key Points: 
  • DUBAI, U.A.E, Aug. 17, 2020 /PRNewswire/ -- Future Market Insights' recently published report concludes that the global manual resuscitator market will expand moderately from 2020-2030.
  • This is providing a fertile ground for manual resuscitator manufacturers to enhance their revenue pools.
  • Such rising cases of lung disorders is prompting healthcare providers to augment their spending on manual resuscitators, providing massive traction to its growth prospects in the future.
  • Koninklijke Philips launched the Augmented Infant Resuscitator in April 2018 to cater to birth asphyxia patients, an add-on device for conventional neonatal bag value mask resuscitators.

Neonatal Infant Care Device Market, Forecast to 2023

Retrieved on: 
Mardi, décembre 3, 2019
Neonatology, Health, Medical specialties, Medicine, Neonatal nursing, Perinatal asphyxia, Neonatal intensive care unit

However, with increasing demand to provide cost-effective care and predict neonatal health, trends such as predictive analytics, multi-parameter analysis, and wireless capabilities have provided a new direction to the classical incubator or neonatal monitor.Since decades, neonatal care devices, such as incubators, ventilators, and cooling devices, to manage birth asphyxia have been high-cost models that have prevented smaller hospitals and low-resource settings to be able to provide access in proportion to the demand for neonatal care.

Key Points: 
  • However, with increasing demand to provide cost-effective care and predict neonatal health, trends such as predictive analytics, multi-parameter analysis, and wireless capabilities have provided a new direction to the classical incubator or neonatal monitor.Since decades, neonatal care devices, such as incubators, ventilators, and cooling devices, to manage birth asphyxia have been high-cost models that have prevented smaller hospitals and low-resource settings to be able to provide access in proportion to the demand for neonatal care.
  • Good neonatal care is still not available in all parts of the world, leading to a disparity in neonatal survival rates.
  • As an example, neonatal cooling devices are still cost prohibitive in most hospitals in Southeast Asia, preventing adequate management of birth asphyxia.
  • Low-cost resuscitation technology, while increasing the availability of care also creates room for errors in ventilation and air pressure.

Philips and global healthcare leaders develop innovative resuscitation device to help reduce neonatal mortality

Retrieved on: 
Mercredi, septembre 26, 2018
Medicine, Health, Neonatology, Childhood, Midwifery, Respiratory diseases, RTT, Infancy, Neonatal resuscitation, Perinatal asphyxia, Perinatal mortality, Infant mortality

Developed in collaboration with the Consortium for Affordable Medical Technologies (CAMTech) at Massachusetts General Hospital Global Health, the Philips Augmented Infant Resuscitator aims to reduce neonatal mortality, especially in parts of the world that are underserved in terms of healthcare.

Key Points: 
  • Developed in collaboration with the Consortium for Affordable Medical Technologies (CAMTech) at Massachusetts General Hospital Global Health, the Philips Augmented Infant Resuscitator aims to reduce neonatal mortality, especially in parts of the world that are underserved in terms of healthcare.
  • Globally, birth asphyxia causes more than 800,000 neonatal deaths annually, and over one million potentially preventable reported stillbirths [1].
  • Effective resuscitation could reduce birth asphyxia related neonatal deaths by 30 percent, and deaths from prematurity by 10 percent [2].
  • [3] Patel J, Posencheg M, Ades A. Proficiency and retention of neonatal resuscitation skills by pediatric residents.